Status:
TERMINATED
Plasma Concentration of Biological Markers in Placental Abruption
Lead Sponsor:
University of Arkansas
Conditions:
Abruptio Placentae
Eligibility:
FEMALE
18-45 years
Brief Summary
This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A ...
Detailed Description
The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to...
Eligibility Criteria
Inclusion
- Age 18 - to 45-years old, inclusive
- Suspected or confirmed PA or phenotypically matched controls
- All modes of delivery
- Gestational age greater than 28 weeks
- Singleton pregnancy
Exclusion
- Intrauterine fetal demise,
- Severe fetal anomalies (infant not expected to survive)
- Inability to communicate in English
Key Trial Info
Start Date :
January 31 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03782168
Start Date
January 31 2019
End Date
August 1 2021
Last Update
September 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205